In pancreatic cancer, Dectin-1 was found to be able to reprogram the tumor-infiltrating macrophages into immune tolerogenic phenotypes and subsequently induce adaptive immunosuppression, which is dependent on the activation of the SYK signaling pathway (35). This evidence concerns the gene CLEC7A and pancreatic neoplasm.